MMP-27-C (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Matrix metalloproteinase-27 (UniProt Q9H306), expressed in HEK293 cells. Suited for ECM protease activity assays, inhibitor profiling, and antibody validation studies in human tissue contexts.
Expression system
HEK293
Cat. #
REC-MMP27C

In stock

SKU
REC-MMP27C
$498.00

Target Overview

MMP-27-C (Recombinant) is a human Matrix metalloproteinase-27 (UniProt Q9H306; gene MMP27) produced by transient expression in HEK293 cells. The full-length human MMP27 open reading frame encodes a 513-amino acid protein. HEK293-derived expression is selected for this target because mammalian post-translational processing — including signal peptide cleavage, disulfide bond formation, and glycosylation — is required for proper folding of the catalytic and hemopexin-like domains characteristic of the MMP family. As a member of the matrix metalloproteinase family, MMP-27 contains the conserved zinc-binding catalytic domain and is reported to localise to the endoplasmic reticulum, a notable distinction from the predominantly secreted MMPs. The protein is capable of degrading extracellular matrix components including fibronectin, laminin, gelatins, and collagens, placing it within the broader MMP substrate-cleavage paradigm used to study ECM remodelling in vitro. Researchers use this recombinant in several experimental contexts: substrate cleavage assays using fluorogenic ECM-derived peptides, inhibitor IC50 determination against the MMP catalytic domain, and as a defined positive-control antigen for antibody validation by Western blot and ELISA. For antibody validation workflows, this recombinant can be paired directly with the Triple Point Biologics matched anti-MMP-27-C antibody (RP-MMP27C), which has been validated for Western blot against human samples. Because the recombinant is expressed in a human cell line, it presents native-like epitopes relevant to experiments using human tissue lysates or cell-conditioned media.

Background

Matrix metalloproteinase-27 (MMP-27; UniProt Q9H306) is one of the least characterised members of the human MMP family. Encoded by the MMP27 gene on chromosome 11q22, the protein shares the canonical MMP architecture — a pro-domain, a zinc-coordinating catalytic domain, and a C-terminal hemopexin-like domain — but its predominantly intracellular localisation in the endoplasmic reticulum distinguishes it from the majority of secreted MMPs. This subcellular distribution raises questions about substrate access and activation mechanisms that remain active areas of basic research. Within the broader MMP family, published transcriptomic and proteomic studies have begun to define conditions under which MMP27 expression is regulated. In a transcriptome-level analysis of osteoclast differentiation, MMP27 was identified among differentially expressed genes associated with bone remodelling pathways, supporting its use as a target in skeletal biology research (Zhang L et al., Mol Biotechnol, 2026; PMID 41339605). Separately, a systematic investigation of the MMP family across head and neck squamous cell carcinoma identified MMP family members, including MMP27, as candidates for prognostic biomarker research within the tumour microenvironment (Liu M et al., J Transl Med, 2023; PMID 36941602). MMP-27 has been studied as a research target in oral oncology: Eichberger et al. (Cancers, 2022; PMID 36011038) reported that loss of MMP-27 protein expression was associated with mandibular bone invasion in oral squamous cell carcinoma, positioning MMP-27 expression status as a variable of interest in tumour invasion studies. This finding motivates the use of well-characterised recombinant MMP-27 as a standard in immunohistochemical scoring and Western blot quantification experiments. At the genome level, MMP27 has appeared in a genome-wide association study examining loci linked to skin autofluorescence in non-diabetic individuals (Vollenbrock CE et al., BMC Genomics, 2022; PMID 36536295), illustrating that MMP family research extends beyond classical matrix remodelling into metabolic and ageing biology. Together, these published data make recombinant MMP-27 a useful tool for researchers designing substrate specificity assays, expression-correlation studies, and antibody development workflows across oncology, bone biology, and connective tissue research. Triple Point Biologics has produced proteinase-family antibodies and recombinant standards since 1994; this recombinant is manufactured under the same quality framework.

Applications

  • Fluorogenic peptide substrate cleavage assay to characterise MMP-27 catalytic activity against ECM-derived sequences
  • Inhibitor IC50 determination for small-molecule MMP inhibitor profiling against the MMP-27 catalytic domain
  • Positive-control antigen for Western blot validation of anti-MMP-27 antibodies in human cell lysate experiments
  • ELISA standard curve preparation for quantification of MMP-27 in conditioned media or tissue extracts
  • Antibody validation by dot-blot or slot-blot alongside matched TPB anti-MMP-27-C antibody (RP-MMP27C)
  • Immunohistochemistry positive-control tissue-section standard for MMP-27 expression scoring studies
  • Biophysical binding assays (SPR, BLI) to characterise interaction of MMP-27 with putative inhibitors or binding partners
  • Substrate specificity profiling by mass spectrometry using recombinant MMP-27 incubated with candidate ECM protein substrates

References

  1. Zhang L et al. Transcriptome Analysis of Differentially Expressed Genes and Molecular Pathways Involved During Osteoclast Differentiation. Mol Biotechnol. 2026. doi:10.1007/s12033-025-01540-3. PMID: 41339605.
  2. Liu M et al. Identification of the MMP family as therapeutic targets and prognostic biomarkers in the microenvironment of head and neck squamous cell carcinoma. J Transl Med. 2023. doi:10.1186/s12967-023-04052-3. PMID: 36941602.
  3. Diao X et al. Melatonin Promotes the Development of Secondary Hair Follicles in Adult Cashmere Goats by Activating the Keap1-Nrf2 Signaling Pathway and Inhibiting the Inflammatory Transcription Factors NFκB and AP-1. Int J Mol Sci. 2023. doi:10.3390/ijms24043403. PMID: 36834812.
  4. Vollenbrock CE et al. Genome-wide association study identifies novel loci associated with skin autofluorescence in individuals without diabetes. BMC Genomics. 2022. doi:10.1186/s12864-022-09062-x. PMID: 36536295.
  5. Eichberger J et al. Loss of MMP-27 Predicts Mandibular Bone Invasion in Oral Squamous Cell Carcinoma. Cancers (Basel). 2022. doi:10.3390/cancers14164044. PMID: 36011038.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; Extracellular matrix

Frequently Asked Questions

What is the expected molecular weight of MMP-27-C (Recombinant) on SDS-PAGE or Western blot?

The full-length human MMP27 open reading frame encodes 513 amino acids, giving a predicted unglycosylated MW of approximately 59 kDa. Because this recombinant is produced in HEK293 cells with native mammalian glycosylation machinery intact, the apparent MW on reducing SDS-PAGE typically runs between 62–68 kDa depending on glycan load. Under non-reducing conditions, intermolecular disulfide-linked species may appear at higher MW. We recommend running 100–200 ng per lane alongside a broad-range marker to resolve the glycoprotein smear characteristic of MMP-family members expressed in mammalian systems.

Is MMP-27-C (Recombinant) the full-length protein or a processed catalytic domain fragment?

This product is produced from the full-length human MMP27 open reading frame (UniProt Q9H306, 513 aa) expressed transiently in HEK293 cells. The signal peptide is cleaved co-translationally, so the secreted/recovered form lacks the N-terminal signal sequence. Both the propeptide and catalytic domains are present, along with the C-terminal hemopexin-like domain. If your experiment specifically requires the isolated catalytic domain or activated (propeptide-removed) form, note the activation state in your assay design and confirm zymogen-vs-active status using the fluorogenic substrate assay described below.

What substrates does MMP-27 cleave and which is recommended for in vitro activity assays?

MMP-27 is reported to cleave fibronectin, laminin, type IV collagen, and gelatins. For routine fluorometric activity assays, a broad-spectrum MMP fluorogenic substrate such as Mca-PLGL-Dpa-AR-NH2 (Ex/Em 328/393 nm) is a practical starting point. Assay in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 10% glycerol — matching the storage buffer exactly — at 37°C. Use 0.1–1 µg recombinant per 100 µL reaction and titrate substrate from 5–100 µM to establish Km. Include 10 mM EDTA or a broad MMP inhibitor (e.g., GM6001) as a negative control.

What starting concentration of MMP-27-C (Recombinant) is recommended for inhibitor IC50 experiments?

For IC50 determination, keep enzyme concentration well below your substrate Km and ideally at or below the Ki of your inhibitor to avoid tight-binding artifacts (Morrison equation territory). A practical starting point is 10–50 nM MMP-27-C in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 37°C. Pre-incubate enzyme with inhibitor for 15–30 min before substrate addition. Confirm linear signal accumulation over the measurement window. EDTA (10 mM) and GM6001 (1 µM final) serve as appropriate positive-inhibition controls given the zinc-dependent catalytic mechanism.

Does the CaCl2 in the storage buffer interfere with downstream assay buffer conditions?

At typical working dilutions the CaCl2 carryover from the storage buffer (5 mM in the stock) is negligible. For example, adding 1 µL of stock to a 100 µL reaction contributes only 0.05 mM CaCl2, well below the 1–5 mM Ca2+ commonly used to support MMP catalytic activity. If your assay is Ca2+-sensitive or uses a chelator, dilute the enzyme into assay buffer first and allow 5 min equilibration on ice. Avoid EGTA/EDTA in the dilution buffer before the final reaction setup, as calcium depletion can destabilize the MMP catalytic domain.

Can I use MMP-27-C (Recombinant) as a positive control for Western blot with the matched RP-MMP27C antibody?

Yes — this is one of the primary reasons REC-MMP27C and RP-MMP27C are co-developed in the same program. Load 50–150 ng of recombinant per lane on a 10% or 12% SDS-PAGE gel under reducing conditions. The RP-MMP27C rabbit polyclonal reliably detects the 62–68 kDa glycoprotein band. This pairing is particularly useful for antibody lot-to-lot validation and for confirming detection sensitivity before moving to low-expressing lysate samples. See the RP-MMP27C product page (/anti-mmp-27c-rabbit-polyclonal-antibody) for recommended primary antibody dilutions.

How much MMP-27-C (Recombinant) should I load for a Western blot positive control lane?

50–150 ng per lane is the recommended range when pairing with RP-MMP27C. Start at 100 ng for initial optimization: this amount reliably produces a detectable band without saturating the signal at standard RP-MMP27C dilutions (typically 1:500–1:2000 for Western blot). If you are running a titration to establish linear detection range for quantitative Western blot work, prepare a 3-point series at 50, 100, and 200 ng. Dilute from the stock into 1× SDS loading buffer immediately before boiling; avoid repeated dilution and freeze-thaw of the working aliquot.

How should I handle, store, and aliquot MMP-27-C (Recombinant) to preserve activity long-term?

Upon receipt, spin briefly at 400 × g, then aliquot into single-use volumes — typically 5–10 µg per tube — in low-binding microcentrifuge tubes. Store at -20°C. The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 10% glycerol) is formulated to stabilize metalloproteinase activity through freeze-thaw; however, repeated freeze-thaw cycles progressively reduce specific activity. Do not store at 4°C for more than 48 hours. For activity assays, thaw on ice and use within 2 hours. Purity is >90% by SDS-PAGE and endotoxin is confirmed <0.1 EU/µg by LAL, so no additional clean-up steps are required before use.

Validation imagery coming soon

Western blot validation figures for REC-MMP27C will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →